CARD9 has been shown to control immune responses downstream of TREM2, CD33, and CD22 in other models of disease (36, –38), although the involvement of CARD9 in AD and most other neurodegenerative disorders remains to be determined. Here, CD33 is linked to Alzheimer disease.